• The Korean Journal of Applied Statistics
• /
• v.29 no.2
• /
• pp.279-289
• /
• 2016

Bioequivalence trials based on higher order crossover designs have recently been conducted for highly variable drugs since the Ministry of Korea Food and Drug Safety (MFDS) added new regulations in 2013 to widen bioequivalence limits for highly variable drugs. However, a statistical discussion of higher order crossover designs have not been discussed yet. This research proposes the statistical inference of bioequivalence based on $3{\times}3$ crossover design and discusses it with the MFDS regulations. An illustrated example is also given.

• Journal of Pharmaceutical Investigation
• /
• v.13 no.3
• /
• pp.115-125
• /
• 1983

제제설계란 제형의 설계 및 그에 따른 처방설정(formulation)을 의미하며 경험적인 제제방법 및 그 기술측면에서의 제제화는 주악 및 첨가물의 종류와 배합비율의 설정등 비교적 단순한 내용을 의미하지만 의약품은 실제적으로 인체에 적용되므로 치료설계상의 연구와 생물약제학적 검토에 의한 유효정과 안전성을 발휘할 수 있도록 설계가 되어야 한다. 또한 약물의 효력은 체내 특정부위에 특정농도의 약물분포가 필요하고, 일정시간 지속되는 것이 요구되므로 약용량도 중요하지만 약물투여 후의 흡수, 체내이행, 대사, 배설등의 상태를 파악하고 이에 미치는 부형제의 영향도 검토하여야 한다. 제제물리학적 측면에서 품질보증을 위하여 preformulation단계에서 주약의 물성검토, 첨가제의 사용량, interaction 및 혼합순서 등과 처방설정 단계에서 제제화에 사용되는 기계장치의 특성 및 능력, 제제화 후의 포장용기 및 포장상태에서의 안정성 등도 면밀히 검토하여야한다. 제제설계란 단순한 dosage form의 design만이 아니고 유효성이 높고, 부작용이 적은 제제를 합리적으로 만드는 기술과 정보의 종합관리로 scale up과정에서 원료, 기계장치, 제조방법, 작업자 등에 의한 품질변동 요인을 극소화하고, 공정의 초기단계에서 즉시 조정될 수 있는 종합관리 system이 필요하다.

• The Korean Journal of Applied Statistics
• /
• v.26 no.4
• /
• pp.675-686
• /
• 2013

The Korea Food and Drug Administration(KFDA) recommends the use of a $2{\times}2$ crossover design to assess the bioequivalence of generic drugs. However, a standard $2{\times}2$ crossover design for bioequivalence trials is often considered problematic due to ethical and economic issues as highly variable drugs are usually required by large numbers of subjects when designing the trial. To overcome this problem a $2{\times}4$ crossover design has been a recommended option as per US regulations; in addition, a $2{\times}3$ crossover design has also recently drawn special attention as an efficient alternative. The current KFDA regulation requires an ANOVA table for every bioequivalence study; however, ANOVA tables of $2{\times}4$ and $2{\times}3$ crossover designs have never been published in the literature. This study shows the derivation of tables of analysis of variance for a $2{\times}4$ cross-over design and a $2{\times}3$ cross-over design. We also suggest a sample size formulas for $2{\times}2$, $2{\times}4$ and $2{\times}3$ crossover designs to provide information on the selection of efficient designs for highly variable drugs.

• 동물약계
• /
• no.76
• /
• pp.2-3
• /
• 2001

[ $\cdot$ ]동물용의약품등 제조업 허가(신고) 변경 $\cdot$동물용의약품등 수입관리자 신규 승인 $\cdot$동물용의약품등 수입자 확인사항 변경 $\cdot$동물용의료용구 제조업 허가사항 변경 $\cdot$국가검정제품의 보관, 표시 및 검정시료의 발췌요령 제정 고시 $\cdot$국가검정동물용의약품 검정기준 개정 고시 $\cdot$동물용의약품공정서 개정 고시 $\cdot$생물학적제제 국가검정 개선 $\cdot$생물학적제제 검정시료 발췌 안내

• The Korean Journal of Applied Statistics
• /
• v.24 no.1
• /
• pp.161-167
• /
• 2011

The primary variables are often systematically related to other influences apart from drug effect. For instance, there may be relationships to covariates such as health conditions or prognostic factors. When a $2{\times}2$ crossover experiment for bioequivalence is designed, the statistical adjustment for the influence of covariates should be considered if some covariates influence the drug effect. Statistical inference for assessing average bioequivalence for a $2{\times}2$ crossover design with covariates is given and an illustrated example is presented with discussion.

• 대한임상약리학회:학술대회논문집
• /
• 2000.04a
• /
• pp.11-12
• /
• 2000

• Korean Journal of Pharmacognosy
• /
• v.4 no.2
• /
• pp.53-58
• /
• 1973

• 대한위암학회:학술대회논문집
• /
• 2005.10a
• /
• pp.29-29
• /
• 2005

• Korean Journal of Environmental Biology
• /
• v.21 no.3
• /
• pp.276-285
• /
• 2003

To control pythium root rot, Bacillus lentimorbus WJ5a17 with high anti-fungal activity against Pythium ultimum was induced from B. lentimorbus WJ5 by gamma radiation ($^{60}Co$). The biocontrollers of FWJ5 and FWJ5a17 were formulated ($1.0\times 10^{11}$) with B. lentimorbus WJ5 and WJ5a17, respectively, The population density of FWJ5 and FWJ5a17 maintained highly up to $1.0\times 10^{9}$ CFU $g^{-1}$ in nursery and field soils until 30 days after treatment. P. ultimum spores germination were inhibited 71.0% and 81.4% by FWJ5 and FWJ5a17, respectively. Pythium root rot of yea pepper, Chinese cabbage and radish were significantly (p < 0.05) controled by one time treatment of FWJ5 and FWJ5a17.

• Journal of the korean veterinary medical association
• /
• v.7 no.5
• /
• pp.52-54
• /
• 1963